Login to Your Account



Deals And M&A NEWS
Allergan plc spotted an opportunity to add an implantable shunt technology to its eye care offering through a $300 million cash acquisition of privately held Aquesys Inc., of Aliso Viejo, Calif.

Incyte Corp. leveraged its positive cash flow to invest in its immuno-oncology future through a license and collaboration agreement with Jiangsu Hengrui Medicine Co. Ltd. to develop and commercialize anti-PD-1 monoclonal antibody SHR-1210.

A risk-defraying pact between Amgen Inc. and Novartis AG will align the companies' early stage efforts to fight Alzheimer's disease behind Novartis' phase I/II oral beta-site APP-cleaving enzyme-1 inhibitor, CNP-520.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: